Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 4/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069808 | 0.82 | NOX1 (0.37) | LMNAGAATSHRNPC1RAB9A | |
| SCHEMBL6137666 | 0.81 | PTGS1 (0.40) | LMNASMN1; SMN2 | |
| SCHEMBL6069800 | 0.81 | MT-CO2 (0.40) | — | |
| SCHEMBL6069681 | 0.79 | LMNA (0.31) | LMNA | |
| SCHEMBL6070036 | 0.73 | FKBP1A (0.35) | NAAATSHR | |
| SCHEMBL6642433 | 0.72 | NOS3 (0.44) | GAATSHR | |
| SCHEMBL6643305 | 0.71 | NOS3 (0.48) | LMNATSHRNPC1SMN1; SMN2 | |
| SCHEMBL6069744 | 0.71 | HSD17B10 (0.46) | GAASMN1; SMN2 | |
| SCHEMBL6070084 | 0.71 | MT-CO2 (0.40) | GAA | |
| SCHEMBL6645276 | 0.69 | NOS3 (0.44) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067667-B2 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-27 | — | — | US | disclosed |
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | JAROCH STEFAN (DE) | 2004-07-01 | — | — | US | disclosed |
| EP-1115708-B1 | AMINOALKYL-3,4-DIHYDROQUINOLINE DERIVATES AS NO-SYNTHASE INHIBITORS | SCHERING AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1115708-A1 | AMINOALKYL-3,4-DIHYDROQUINOLINE DERIVATES AS NO-SYNTHASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017167-A1 | AMINOALKYL-3,4-DIHYDROQUINOLINE DERIVATES AS NO-SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | NOS3, NOS1, NOS2 | NAAA 127/4885LMNA 3738/4885PDE4A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.